CD38 and lung carcinoma: Furthermore, in murine models of lung cancer and melanoma, acquired resistance to anti‐PD‐1/PD‐L1 agents is associated with CD38 upregulation on tumor cells, thereby leading to CD38‐mediated CD8+ T‐cell suppression via adenosine receptor signaling.18